Healthcare • Biotechnology
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if GMAB is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
41 top institutions tracked
Last 13F trend: accumulating (light)
Unlock crowding heatmapUnlock filer discoverySentiment: unknown
No recent insider trades detected.
Red flags: 0
292 filers reported a long position in GMAB for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| Paradigm Biocapital Advisors LP | $360.8M | 13.1M | +64.8% |
| Orbis Allan Gray Ltd | $312.3M | 11.4M | -12% |
| ALLIANCEBERNSTEIN L.P. | $231.9M | 8.6M | -9.5% |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $188.6M | 6.9M | +178.8% |
| Deep Track Capital, LP | $155.2M | 5.7M | +54.2% |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $136.7M | 5M | Unchanged |
| BlackRock, Inc. | $128.3M | 4.7M | +3% |
| Sofinnova Investments, Inc. | $111.1M | 4M | +437.7% |
| RENAISSANCE TECHNOLOGIES LLC | $96.6M | 3.5M | -20.3% |
| TWO SIGMA INVESTMENTS, LP | $96.3M | 3.5M | +49.9% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.